C CENTESSA PHARMACEUTICALS PLC
| Market Cap | $6.14B |
| P/E Ratio | — |
| Forward P/E | -20.93 |
| Dividend Yield | — |
| Beta | — |
| 52W Range | $10.71 - $39.86 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Lee Ainslie Maverick Capital | 0.44% | $41.11M | 1,643,724 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 22 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Anderson Karen M.Chief People Officer | Sale | 41,076 | $30.12 | $1.24M | 26 Mar 2026 | 26 Mar 2026 |
| Weinhoff Gregory MChief Business Officer | Sale | 23,998 | $30.00 | $719.94K | 26 Mar 2026 | 26 Mar 2026 |
| Anderson Karen M.Chief People Officer | Sale | 10,043 | $28.10 | $282.21K | 17 Mar 2026 | 16 Mar 2026 |
| Anderson Karen M.Chief People Officer | Sale | 64,768 | $28.21 | $1.83M | 16 Mar 2026 | 16 Mar 2026 |
| Weinhoff Gregory MChief Business Officer | Sale | 11,943 | $27.16 | $324.34K | 13 Mar 2026 | 13 Mar 2026 |
| Weinhoff Gregory MChief Business Officer | Sale | 61,253 | $26.17 | $1.60M | 13 Mar 2026 | 13 Mar 2026 |
| Anderson Karen M.Chief People Officer | Sale | 12,068 | $27.13 | $327.44K | 13 Mar 2026 | 13 Mar 2026 |
| Anderson Karen M.Chief People Officer | Sale | 107,961 | $26.15 | $2.82M | 13 Mar 2026 | 13 Mar 2026 |
| HUSSAIN IQBAL JChief Legal Officer | Sale | 38,951 | $25.15 | $979.66K | 02 Feb 2026 | 03 Feb 2026 |
| Iqbal J HussainChief Legal Officer | Sale | 38,951 | $25.15 | $979.66K | 02 Feb 2026 | 03 Feb 2026 |
| HUSSAIN IQBAL JChief Legal Officer | Sale | 1,010 | $25.01 | $25.26K | 30 Jan 2026 | 03 Feb 2026 |
| Iqbal J HussainChief Legal Officer | Sale | 1,010 | $25.01 | $25.26K | 30 Jan 2026 | 03 Feb 2026 |
| Accardi Mario AlbertoPresident, Orexin Program | Sale | 2,568 | $29.21 | $75.01K | 09 Dec 2025 | 09 Dec 2025 |
| Accardi Mario AlbertoPresident, Orexin Program | Sale | 7,432 | $28.70 | $213.28K | 09 Dec 2025 | 09 Dec 2025 |
| Accardi Mario AlbertoPresident, Orexin Program | Sale | 10,000 | $30.00 | $300.00K | 08 Dec 2025 | 08 Dec 2025 |
| HUSSAIN IQBAL JGeneral Counsel | Sale | 6,000 | $27.64 | $165.84K | 17 Nov 2025 | 18 Nov 2025 |
| Bush Tia LChief Technology & Quality Ofc | Sale | 40,000 | $28.00 | $1.12M | 17 Nov 2025 | 18 Nov 2025 |
| Bush Tia LChief Technology & Quality Ofc | Sale | 40,000 | $26.00 | $1.04M | 12 Nov 2025 | 13 Nov 2025 |
| Accardi Mario AlbertoPresident, Orexin Program | Sale | 8,000 | $25.00 | $200.00K | 27 Oct 2025 | 27 Oct 2025 |
| Mario Alberto AccardiPresident, Orexin Program | Sale | 8,000 | $25.00 | $200.00K | 27 Oct 2025 | 27 Oct 2025 |
| HUSSAIN IQBAL JGeneral Counsel | Sale | 6,000 | $22.41 | $134.44K | 15 Oct 2025 | 16 Oct 2025 |
| Iqbal J HussainGeneral Counsel | Sale | 6,000 | $22.41 | $134.44K | 15 Oct 2025 | 16 Oct 2025 |
Frequently Asked Questions
What is CNTA stock price today?
CENTESSA PHARMACEUTICALS PLC (CNTA) is currently trading at $39.69. The stock has a 52-week range of $10.71 to $39.86 and a market capitalization of $6.14B.
Is CNTA a good stock to buy in 2026?
CENTESSA PHARMACEUTICALS PLC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +203.9%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling CNTA stock?
There have been 22 insider transactions for CNTA in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has CNTA stock performed over the past year?
CENTESSA PHARMACEUTICALS PLC (CNTA) has returned +203.9% over the past 12 months. The stock traded between $10.71 and $39.86 during this period, and is currently at $39.69.
Which hedge funds own CNTA (CENTESSA PHARMACEUTICALS PLC)?
1 tracked hedge funds currently hold CNTA in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is CNTA's market cap and valuation?
CENTESSA PHARMACEUTICALS PLC (CNTA) has a market capitalization of $6.14B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is CNTA's revenue and profitability?
CENTESSA PHARMACEUTICALS PLC reported revenue of $15.00M with net income of N/A and a profit margin of N/A. The stock has a beta of N/A.
What sector is CNTA in and who are its biggest institutional holders?
CENTESSA PHARMACEUTICALS PLC (CNTA) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.